- Home
- FFWM vs ZURA Comparison
FFWM vs ZURA Comparison
Compare FFWM & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFWM | ZURA |
|---|---|---|
| Founded | 1990 | 2022 |
| Country | United States | United States |
| Employees | 485 | 40 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 455.4M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | FFWM | ZURA |
|---|---|---|
| Price | $5.91 | $3.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.17 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 4.3M | 656.9K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,373,000.00 | N/A |
| Revenue This Year | $56.34 | N/A |
| Revenue Next Year | $10.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.59 | $1.00 |
| 52 Week High | $6.72 | $7.25 |
Technical Indicators
Market Signals| Indicator | FFWM | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 25.83 |
| Support Level | $5.44 | $3.33 |
| Resistance Level | $5.97 | $4.12 |
| Average True Range (ATR) | 0.19 | 0.31 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 80.63 | 12.25 |
Price Performance
Historical ComparisonAbout FFWM First Foundation Inc.
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.